BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing novel antibacterial products for multi-drug resistant (MDR) infections, announced today that all proposals by the Board of Directors were approved by shareholders at the Annual General Meeting (AGM). The company, which recently achieved first patient first visit (FPFV) for its global Phase 3 trial of BV100, is focused on bringing this therapeutic option to patients in dire need.
Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude for shareholders' continued trust and support. He noted the company's commitment to progressing alpibectir and the preclinical pipeline with partners. Dr. Mah also thanked Dr. William Jenkins for his contributions and welcomed Ms. Simona Skerjanec to the Board of Directors.
Key approvals included the 2025 Annual Report, financial statements, and auditors' reports. Shareholders re-elected Seng Chin Mah as Chairman, along with David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Ms. Simona Skerjanec was elected as a new Board member. The maximum aggregate compensation for the Board of Directors until the 2027 AGM and for the Executive Committee for fiscal year 2027 were also approved.
The minutes and relevant documents, including the Annual Report, are available on the company's website. See the Annual Report and AGM documents.
BioVersys focuses on novel antibacterial treatments for life-threatening infections caused by MDR bacteria, leveraging two internal technology platforms: TRIC and Ansamycin Chemistry. Its lead program, BV100, targets Acinetobacter baumannii infections in Phase 3, while alpibectir for tuberculosis is in Phase 2 with GlaxoSmithKline (GSK) and a consortium. The company is based in Basel, Switzerland.
